Peyronie's Disease: Etiology, Epidemiology and Medical Treatment

Urologic Clinics of North America - Tập 32 Số 4 - Trang 469-478 - 2005
Jason M. Greenfield1, Laurence A. Levine2
1Rush Univeristy Medical Center, PB Suite 348, Chicago, IL 60612, USA. [email protected]
2Rush Univeristy Medical Center, 1725 W. Harrison Street, PB Suite 348, Chicago, IL 60612, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Murphy, 1972, Miscellanea: Peyronie's disease (fibrous cavernositis), 485

Wesson, 1943, Peyronie's disease (plastic induration) cause and treatment, J Urol, 49, 350, 10.1016/S0022-5347(17)70554-X

Hunter J. Of the treatment of occasional symptoms of the gonorrhea. In: Nicol G, Johnson J, editors. A treatise on the venereal disease. 2nd ed. Philadelphia: J. Webster, 1818. p. 88–9.

Abernethy, 1828

Levine, 1997, Treatment of Peyronie's disease with intralesional verapamil injection, J Urol, 158, 1395, 10.1016/S0022-5347(01)64224-1

Devine, 1997, Proposal: trauma as the cause of the Peyronie's lesion, J Urol, 157, 285, 10.1016/S0022-5347(01)65361-8

Zargooshi, 2004, Trauma as the cause of Peyronie's disease: penile fracture as a model of trauma, J Urol, 172, 186, 10.1097/01.ju.0000132144.71458.86

Magee, 2002, Gene expression profiles in the peyronie's disease plaque, Urology, 59, 451, 10.1016/S0090-4295(01)01578-3

Qian, 2004, Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture, Urology, 64, 399, 10.1016/j.urology.2004.04.006

Cole A. Increased endogenous inhibitors of collagenases within Peyronie's plaques may represent a scar remodeling disorder [Abstr 944]. Annual Meeting of the American Urological Association; San Antonio, TX. May 21–26, 2005.

Davila HH, Ferrini MG, Rajfer J, et al. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. BJU Int 91(9):830–8.

Haag SM, Hauck EW, Altinkilic B, et al. Alterations in the transforming-growth-factor-beta pathway as a possible risk factor in the pathogenesis of Peyronie's disease [Abstr 939]. Annual Meeting of the American Urological Association; San Antonio, TX. May 21–26, 2005.

Davila HH, Magee TR, Zuniga F, et al. Plasminogen activator inhibitor-1 (PAI-1) is increased in human Peyronie's disease [Abstr 943]. Annual Meeting of the American Urological Association; San Antonio, TX. May 21–26, 2005.

Polkey, 1928, ID induratio penis plastica, Urol Cut Rev, 32, 287

Ludvik, 1968, Die Radiumbehandlung der induratio penis plastica, Z Urol Nephrol, 61, 319

Devine, 1997, Introduction to Peyronie's disease, J Urol, 157, 272, 10.1016/S0022-5347(01)65358-8

La Rochelle JC, Levine LA. Survey of primary care physisicans and urologists regarding Peyronie's disease. [Abstr 941]. Annual Meeting of the American Urological Association; San Antonio, TX. May 21–26, 2005.

Lindsay, 1991, The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984, J Urol, 146, 1007, 10.1016/S0022-5347(17)37988-0

Sommer, 2002, Epidemiology of Peyronie's disease, Int J Impot Res, 14, 379, 10.1038/sj.ijir.3900863

Mulhall, 2004, Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening, J Urol, 171, 2350, 10.1097/01.ju.0000127744.18878.f1

Gelbard, 1990, The natural history of Peyronie's disease, J Urol, 144, 1376, 10.1016/S0022-5347(17)39746-X

Kadioglu, 2002, A retrospective review of 307 men with Peyronie's disease, J Urol, 168, 1075, 10.1016/S0022-5347(05)64578-8

Mulhall JP, Guhring P, Depierro C. Intralesional verapamil prevents progression of Peyronie's disease [Abstr 936]. Annual Meeting of the American Urological Association; San Antonio, TX. May 21–26, 2005.

Levine, 2003, Peyronie's disease in younger men: Characteristics and treatment results, J Androl, 24, 27, 10.1002/j.1939-4640.2003.tb02634.x

Tefekli, 2001, Peyronie's disease in men under 40: characteristics and outcome, Int J Impot Res, 13, 18, 10.1038/sj.ijir.3900635

Briganti, 2003, Clinical presentation of Peyronie's disease in young patients, Int J Impot Res, 15, S44

Williams, 1970, The natural history of Peyronie's disease, J Urol, 103, 75, 10.1016/S0022-5347(17)61894-9

Kadioglu, 2001, Lessons learned from 307 men with Peyronie's disease, J Urol, 165, 202

Scott, 1948, A new concept in the treatment of Peyronie's disease, South Med J, 41, 173, 10.1097/00007611-194802000-00017

Akkus, 1994, Is colchicine effective in Peyronie's disease? A pilot study, Urology, 44, 291, 10.1016/S0090-4295(94)80155-X

Kadioglu, 2000, Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome, Int J Impot Res, 12, 169, 10.1038/sj.ijir.3900519

Zarafonetis, 1959, Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba), J Urol, 81, 770, 10.1016/S0022-5347(17)66108-1

Hasche-Klunder, 1978, Treatment of peyronie's disease with para-aminobenzoacidic potassium (POTOBA) (author's transl), Urologe A, 17, 224

Weidner, 1999, Randomized prospective placebo-controlled therapy of Peyronie's disease (IPP) with Potaba∗ (aminobenzoate potassium), J Urol, 6, 205, 10.1097/00005392-199904010-00823

Ralph, 1992, The treatment of Peyronie's disease with tamoxifen, Br J Urol, 70, 648, 10.1111/j.1464-410X.1992.tb15836.x

Colletta, 1990, Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts, Br J Cancer, 62, 405, 10.1038/bjc.1990.307

Teloken, 1999, Tamoxifen versus placebo in the treatment of Peyronie's disease, J Urol, 162, 2003, 10.1016/S0022-5347(05)68087-1

Biagiotti, 2001, Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report, BJU Int, 88, 63, 10.1046/j.1464-410x.2001.02241.x

Kelly, 1985, Pathways of protein secretion in eukaryotes, Science, 230, 25, 10.1126/science.2994224

Aggeler, 1984, Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts, J Cell Biol, 98, 1662, 10.1083/jcb.98.5.1662

Lee, 1990, Calcium antagonists retard extracellular matrix production in connective tissue equivalent, J Surg Res, 49, 463, 10.1016/0022-4804(90)90197-A

Martin, 2002, Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea, J Urol, 168, 2483, 10.1016/S0022-5347(05)64173-0

Teasley, 1954, Peyronie's disease a new approach, J Urol, 71, 611, 10.1016/S0022-5347(17)67832-7

Bodner, 1954, Peyronie's disease: cortisone-hyaluronidase-hydrocortisone therapy, J Urol, 72, 400, 10.1016/S0022-5347(17)67602-X

Winter, 1975, Peyronie's disease: results with dermo-jet injection of dexamethasone, J Urol, 14, 898, 10.1016/S0022-5347(17)67169-6

Williams, 1980, The non-surgical treatment of Peyronie's disease, Br J Urol, 52, 392, 10.1111/j.1464-410X.1980.tb03067.x

Gelbard, 1982, Collagenase for Peyronie's disease: experimental studies, Urol Res, 10, 135, 10.1007/BF00255956

Gelbard, 1985, The use of collagenase in the treatment of Peyronie's disease, J Urol, 134, 280, 10.1016/S0022-5347(17)47123-0

Gelbard, 1993, Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study, J Urol, 149, 56, 10.1016/S0022-5347(17)35998-0

Levine, 1994, Intralesional verapamil injection for the treatment of Peyronie's disease, J Urol, 151, 1522, 10.1016/S0022-5347(17)35291-6

Rehman, 1998, Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study, Urology, 51, 620, 10.1016/S0090-4295(97)00700-0

Levine, 2002, Experience with intraplaque injection of verapamil for Peyronie's disease, J Urol, 168, 621, 10.1016/S0022-5347(05)64691-5

Duncan, 1991, Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma, Scand J Urol Nephrol, 25, 89, 10.3109/00365599109024539

Wegner, 1995, Treatment of Peyronie's disease with local interferon-alpha 2b, Eur Urol, 28, 236, 10.1159/000475057

Wegner, 1997, Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie's disease, Eur Urol, 32, 190, 10.1159/000480857

Judge, 1997, Intralesional interferon in the treatment of Peyronie's disease: a pilot study, Br J Urol, 79, 40, 10.1046/j.1464-410X.1997.02849.x

Ahuja, 1999, A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease, J Androl, 20, 444, 10.1002/j.1939-4640.1999.tb02539.x

Dang, 2004, Intralesional interferon-alpha-2B injections for the treatment of Peyronie's disease, South Med J, 97, 42, 10.1097/01.SMJ.0000056658.60032.D3

Hellstrom, 2003, A single-blind, multi-center, placebo-controlled study to assess the safety and efficacy of intralesional interferon alpha-2b in the non-surgical treatment of Peyronie's disease, J Urol, 169, 274

Levine, 2003, Review of current nonsurgical management of Peyronie's disease, Int J Impot Res, 15, S113, 10.1038/sj.ijir.3901084

Manikandan, 2002, Evaluation of extracorporeal shock wave therapy in Peyronie's disease, Urology, 60, 795, 10.1016/S0090-4295(02)01970-2

Lebret, 2002, Extracorporeal shock wave therapy in the treatment of Peyronie's disease: experience with standard lithotriptor (siemens-multiline), Urology, 59, 657, 10.1016/S0090-4295(02)01527-3

Hauck, 2000, Extracorporeal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach, Eur Urol, 38, 663, 10.1159/000020359

Riedl, 2000, Iontophoresis for treatment of Peyronie's disease, J Urol, 163, 95, 10.1016/S0022-5347(05)67981-5

Montorsi, 2000, Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results, J Androl, 21, 85, 10.1002/j.1939-4640.2000.tb03279.x

Di Stasi, 2003, Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease, BJU Int, 91, 825, 10.1046/j.1464-410X.2003.04242.x

Di Stasi, 2004, A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease, J Urol, 171, 1605, 10.1097/01.ju.0000116450.82816.2c

Levine, 2003, Tunica albuginea tissue analysis after electromotive drug administration, J Urol, 169, 1775, 10.1097/01.ju.0000056153.47716.d0

Levine, 2003, A double-blind, placebo-controlled trial of electromotive drug administration (EMDA) using verapamil vs. saline for Peyronie's disease: preliminary results, J Urol, 169, 274

Ojingwa, 2003, Electrical stimulation of wound healing, J Invest Dermatol, 121, 1, 10.1046/j.1523-1747.2003.12454.x

Prieto Castro, 2003, Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease, BJU Int, 91, 522, 10.1046/j.1464-410X.2003.04134.x

Mirone, 2000, Ultrasound-guided ESWT in Peyronie's disease plaques, Arch Ital Urol Androl, 72, 384

Mirone, 1999, Our experience on the association of a new physical and medical therapy in patients suffering from induratio penis plastica, Eur Urol, 36, 327, 10.1159/000020013

Cavallini, 2002, Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease, BJU Int, 89, 895, 10.1046/j.1464-410X.2002.02738.x

Levine, 2003, Establishing a standardized evaluation of the man with Peyronie's disease, Int J Impot Res, 15, S103, 10.1038/sj.ijir.3901083